Recently published article has described that BPC 157 had huge potential as a therapy to conservatively treat or aid recovery in hypovascular and hypocellular soft tissues such as tendon and ligaments
In the research chemical market, there are a lot of grifters who are not spending money on the things they should be doing when they manufacture. According to the NIH, BPC-157 demonstrates therapeutic potential across a broad range of musculoskeletal injuries through its angiogenic, anti-inflammatory, cytoprotective and tissue-regenerative properties However, despite this promise, and growing interest in athletic and online communities, human data is exceedingly sparse. As of August 2025, only three pilot studies had been conducted on the human use of BPC-157
Adverse reactions after a B12 injection may include: A feeling of tightness in the chest Anaphylaxis (difficulty breathing or swallowing) Chest pain Congestive heart failure Heart palpitations Pulmonary edema Rapid heartbeat (tachycardia) Shortness of breath Vascular thrombosis Musculoskeletal Effects Your musculoskeletal system makes up your bones, tendons, cartilage, and connective tissues
BPC 157 upregulates the expression of growth hormone receptors in tendon fibroblasts, which are the cells responsible for building and repairing connective tissue
